drugset
drugset / Trial / NCT03677557

Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment

NCT03677557 ↗

Phase 4 Unknown 30 enrolled Ottawa Hospital Research Institute Octapharma · collab
NaSingle-groupOpen-labelTreatment

Summary

Patients with primary or secondary immunodeficiency disease who have developed adverse reactions to products available on the market such as Cuvitru® (Shire), Hizentra® (CSL Behring) or 10% Gammunex® (Grifols), may benefit from utilizing 16.5% Cutaquig® (Octapharma).

Timeline

Start
2018-09-19
Primary completion
2021-08-31
Completion
2021-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject CUTAQUIG Protein / enzyme biologic 16.5 % Subcutaneous

Indications

acquired immunodeficiency inborn error of immunity